New combo is a maintenance treatment for virologically suppressed HIV-1
Researchers find opioid-agonist treatment saves lives and money compared with detox
Tirasemtiv did not differentiate itself from placebo in phase 3 study
Instead of targeting CD19 on the surface of cancer cells, new approach targets CD22
Four in 10 U.S. cases and deaths are linked to risk factors we can change
Approach could help slow growth of antibiotic-resistant bacteria
Needle length and dose target patients weighing 16.5 to 33 pounds
Five sepsis deaths had been reported in late-phase trials
Patients can avoid long drives to distant specialists
In study, progression-free survival was superior to Rituxan-based therapy


Right or Left? In Colorectal Cancer, Side Matters

Eric Van Cutsem, MD, PhD, Co-Chairman of the 2017 ESMO World Congress on Gastrointestinal Cancer, explains why side matters in colorectal cancer. Left-sided tumors have different and often better outcomes, responding better to some therapies than their right-side counterparts. However, research is zeroing in on treatments to fight right-side tumors more effectively.

2017 ESMO World Congress on Gastrointestinal Cancer

P&T November 2017
Table of Contents


The animus toward placebos arises from the notion that the symptoms they alleviate must belong mostly to psychosomatic illnesses. But lately the mindset that underlies placebo disparagement has been fading. The author talks with experts about placebo research, including implications for provider–patient encounters.
Idarucizumab is the first reversal agent approved for the direct thrombin inhibitor dabigatran. The authors summarize the findings from the clinical trial series and describe case reports, post-marketing data, and ongoing studies.
Approved by the FDA in 2015, idarucizumab is indicated for patients with life-threatening or uncontrolled bleeding, as well as in cases where rapid dabigatran reversal is needed for urgent and emergent procedures. The authors present seven case reports on six patients at a large urban academic medical center.


Medication Errors
Safety requires mindfulness
Prescription: Washington
Medicare allows add-on payments to hospitals for some new products
New Drugs/Drug News
Approvals, new indications, regulatory activities, and more
Aminolevulinic acid hydrochloride (Gleolan) for the visualization of malignant tissue during surgery; delafloxacin (Baxdela) for certain acute bacterial skin infections; and glecaprevir/pibrentasvir (Mavyret) for chronic HCV infection
Drug Forecast
Lixisenatide (Adlyxin), a once-daily incretin mimetic injection for type-2 diabetes